LAUNCH & PATIENT ACCESS PLENARY Welcome to the Future: What I Know Now, That I Wish I Knew Then
Friday, June 2, 2023 01:45 PM - 03:15 PM
Amphitheatre Bleu
LAUNCH & PATIENT ACCESS
Plenary
Chair
Phil Vanek, PhD, CTO & Partner, Gamma Biosciences, USA
Speakers
Konstantina Katcheves, MS, JD, Vice President, Business Development, Bristol-Myers Squibb, USA
Geoff MacKay, President & CEO AVROBIO Inc, USA
Sarah Nikiforow, MD, PhD, Assistant Professor of Medicine, Harvard Medical School, USA
Leigh Turner, PhD, Professor, University of California, Irvine, USA
Celia Witten, PhD, Deputy Director, Center for Biologics Evaluation and Research – FDA, USA
Taking a retrospective approach, this session explores what needs to happen in the coming years to realize the potential of advanced therapies including cell, gene, and tissue engineering.
The session will integrate important perspectives that will shape post-launch success focusing on investment, scaling manufacturing and global distribution, driving patient access, integrating into clinical practice, and navigating regulatory oversight to achieve market success and greater global availability.
Phil Vanek, PhD, CTO & Partner, Gamma Biosciences, USA
Speakers
Konstantina Katcheves, MS, JD, Vice President, Business Development, Bristol-Myers Squibb, USA
Geoff MacKay, President & CEO AVROBIO Inc, USA
Sarah Nikiforow, MD, PhD, Assistant Professor of Medicine, Harvard Medical School, USA
Leigh Turner, PhD, Professor, University of California, Irvine, USA
Celia Witten, PhD, Deputy Director, Center for Biologics Evaluation and Research – FDA, USA
Taking a retrospective approach, this session explores what needs to happen in the coming years to realize the potential of advanced therapies including cell, gene, and tissue engineering.
The session will integrate important perspectives that will shape post-launch success focusing on investment, scaling manufacturing and global distribution, driving patient access, integrating into clinical practice, and navigating regulatory oversight to achieve market success and greater global availability.
